Tenax Therapeutics (NASDAQ: TENX) insider transactions
In the twelve months to 10 November 2026, executives and directors of Tenax Therapeutics reported 0 open-market sales and 27 open-market purchases of 3,711,172 shares ($6.6m), by 8 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 21 October 2026 | ADAR1 Capital Management, LLC | — | Open-market purchase | +331,979 | $1.66 | 7,447,000 | Form 4 |
| 20 October 2026 | ADAR1 Capital Management, LLC | — | Open-market purchase | +254,342 | $1.60 | 7,115,021 | Form 4 |
| 19 October 2026 | ADAR1 Capital Management, LLC | — | Open-market purchase | +336,528 | $1.51 | 6,860,679 | Form 4 |
| 16 September 2026 | Doogan Declan | Director | Open-market purchase | +53,000 | $1.92 | 55,274 | Form 4 |
| 15 September 2026 | Giordano Christopher Thomas | CEO | Open-market purchase | +4,850 | $1.82 | 22,174 | Form 4 |
| 11 September 2026 | Staab Thomas R Ii | Chief Financial Officer | Open-market purchase | +5,675 | $1.94 | 15,675 | Form 4 |
| 11 September 2026 | Giordano Christopher Thomas | CEO | Open-market purchase | +6,000 | $1.88 | 17,324 | Form 4 |
| 3 September 2026 | ADAR1 Capital Management, LLC | — | Open-market purchase | +900,000 | $1.78 | 6,524,151 | Form 4 |
| 2 September 2026 | Schneeberger Daniel | — | Open-market purchase | +187,704 | $1.80 | 5,624,151 | Form 4 |
| 1 September 2026 | Schneeberger Daniel | — | Open-market purchase | +179,058 | $1.80 | 5,436,447 | Form 4 |
| 31 August 2026 | Schneeberger Daniel | — | Open-market purchase | +403,571 | $1.79 | 5,257,389 | Form 4 |
| 24 August 2026 | Schneeberger Daniel | — | Open-market purchase | +107,374 | $1.75 | 4,853,818 | Form 4 |
| 21 August 2026 | Schneeberger Daniel | — | Open-market purchase | +716,369 | $1.77 | 4,746,444 | Form 4 |
| 20 August 2026 | Schneeberger Daniel | — | Open-market purchase | +202,124 | $1.78 | 4,030,075 | Form 4 |
| 13 July 2026 | Giordano Christopher Thomas | CEO | Option exercise | +219 | $3.55 | 2,824 | Form 4 |
| 13 July 2026 | Giordano Christopher Thomas | CEO | Option exercise | +8,500 | $5.94 | 11,324 | Form 4 |
| 11 May 2026 | Staab Thomas R Ii | Chief Financial Officer | Grant or award | +10,000 | — | 10,000 | Form 4 |
| 9 December 2025 | Rich Stuart | Chief Medical Officer | Open-market purchase | +2,500 | $10.22 | 5,266 | Form 4 |
| 8 December 2025 | Rich Stuart | Chief Medical Officer | Open-market purchase | +2,500 | $10.10 | 5,000 | Form 4 |
| 4 December 2025 | Rich Stuart | Chief Medical Officer | Open-market purchase | +2,500 | $9.20 | 2,500 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Tenax Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.